As gene editing technologies gain more traction, companies producing the new technologies are attracting more money from investors. One such company is CRISPR Therapeutics of Switzerland that has a number of preclinical projects investigating gene editing for therapeutic use.
Merck & Co Inc has announced plans to acquire privately-held Afferent Pharmaceuticals of San Mateo, California, US for up to $1.25 billion depending on the achievement of specific clinical and commercial milestones.
Jazz Pharmaceuticals Plc, a Dublin-based, Nasdaq-listed company that has built a diversified pharmaceutical business through acquisitions, has made an offer to acquire Celator Pharmaceuticals Inc and its late-stage product for treating acute myeloid leukaemia (AML) for about $1.5 billion.
A UK-based gene therapy company, Freeline Therapeutics, has received a third investment from the UCL Technology Fund, which supports research from University College London. The fund is managed by Albion Ventures in collaboration with UCL Business, the university’s technology transfer office.
Pfizer Inc has completed its $5.2 billion acquisition of Anacor Pharmaceuticals Inc, a US company that is developing small molecule therapeutics using an element in nature called boron. Boron is ingested through the consumption of fruits, vegetables, milk and coffee.
Italy-based MolMed SpA has become the seventh company to get a positive recommendation from the European regulator to market an advanced therapy medicinal product, a group that includes cell and gene therapies as well as tissue-engineered products.
As gene editing technologies gain traction in laboratories around the world, companies producing the new technologies are attracting more money from investors. An example is CRISPR Therapeutics which has a number of preclinical projects where it is investigating gene editing for therapeutic use.
Researchers at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, have discovered an antibody that can activate a protein called Bak and trigger cell death. In healthy cells Bak remains inert. But when a cell receives a signal to die, the protein mobilises to kill the malignant cell.
Researchers at KU Leuven in Belgium have discovered that the tumour protein 53 (TP53) knows exactly where to bind to a DNA sequence to prevent cancer. Once bound to this location, the protein can activate the right genes to repair damaged cells.
A group of 25 bioscience academics and genomic entrepreneurs have published a paper in Science, calling for support of a project to ‘write’ a synthetic human genome. This comes more than a decade after the Human Genome Project successfully sequenced, or ‘read,’ the three billion DNA base pairs that make up the human genome.